Decreased in‐hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID‐19. Issue 9 (8th May 2021)

• Record Type: Journal Article
• Authors: Haji Aghajani, Mohammad; Moradi, Omid; Amini, Hossein; Azhdari Tehrani, Hamed; Pourheidar, Elham; Rabiei, Mohammad M.; Sistanizad, Mohammad
• Other Names: Luo Guangxiang (George) guestEditor.; Ly Hinh guestEditor.; Gao Shou‐Jiang guestEditor.
• Is Part Of: Journal of medical virology. Volume 93:Issue 9(2021)
• Page Start: 5390
• Page End: 5395
• Publication Date: 2021-05-08
• Subjects: aspirin -- cohort study -- COVID‐19 -- mortality -- SARS coronaviruses -- thromboembolism; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27053
• Languages: English
• ISSNs: 0146-6615

Abstract

Highlights: Aspirin administration decrease the rate of mortality in hospitalized patients with severe COVID‐19, independently. Although the crude analysis showed higher mortality rate in patients recieved aspirin, these patients have higher rate of underlying conditions. By performing stepwise COX regression analysis and adjusting the effect of comorbidities, aspirin administration was protective in hospitalized patients with severe COVID‐19. Abstract: Hypercoagulability and thrombosis caused by coronavirus disease 2019 (COVID‐19) are related to the higher mortality rate. Because of limited data on the antiplatelet effect, we aimed to evaluate the impact of aspirin add‐on therapy on the outcome of the patients hospitalized due to severe COVID‐19. In this cohort study, patients with a confirmed diagnosis of severe COVID‐19 admitted to Imam Hossein Medical Center, Tehran, Iran from March 2019 to July 2020 were included. Demographics and related clinical data during their hospitalization were recorded. The mortality rate of the patients was considered as the primary outcome and its association with aspirin use was assessed. Nine hundred and ninety‐one patients were included, of that 336 patients (34%) received aspirin during their hospitalization and 655 ones (66%) did not. Comorbidities were more prevalent in the patients who were receiving aspirin. Results from the multivariate COX proportional model demonstrated a significant independent association between aspirin use and reduction in the risk of in‐hospital mortality (0.746 [0.560–0.994], p = 0.046). Aspirin use in hospitalized patients with COVID‐19 is associated with a significant decrease in mortality rate. Further prospective randomized controlled trials are needed to assess the efficacy and adverse effects of aspirin administration in this population.